Arthropods (Dec 2022)
Laboratory and field evaluation of Sumilarv 0.5G, a commercial Pyriproxyfen on the larval strains of Aedes aegypti and Aedes albopictus
Abstract
This study was conducted to evaluate the laboratory and field bioassay of 4th instar larvae of Aedes aegypti and Aedes albopictus to Sumilarv 0.5G, an insect growth regulator larvicide that is conventionally used for dengue vector control. We used three treatments of Sumilarv 0.5G (1 ppm, 2 ppm, and 4 ppm) against the dengue vector mosquito larvae. Laboratory bioassay showed that dosages of Sumilarv 0.5G at 2 mg/L (2 ppm) and 4 mg/L (4 ppm) were adequate to exert 95.7% and 98.9% inhibition of emergence (%IE) in Cagayan de Oro strains of Ae. aegypti larvae. The same doses yielded 96.9% and 99.1% percent emergence inhibition (%IE) on Ae. albopictus larvae. The dosage of 1 mg/L (1 ppm) of Sumilarv 0.5G yielded 92.2% IE in Ae. aegypti and 80.1% IE in Ae. albopictus. Field bioassay at 2 ppm and 4 ppm Sumilarv 0.5G doses showed 70% and 91% inhibition of emergence in Ae. aegypti while Ae. albopictus yielded 97% and 98% inhibition of emergence for the same doses. One ppm dosage of Sumilarv 0.5G produced 71% IE in Ae. aegypti and 82.4% IE in Ae. albopictus. Based on the results, the lowest recommended application dosage (2 ppm) was found effective, but the most significant efficacy obtained was from the 4 ppm dosage. Sumilarv 0.5G qualifies as a tool for vector control on Ae. aegypti and Ae. albopictus.
